SCHEMBL20519817

SCHEMBL20519817

O=CN(CCNC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21)c1cccc(-c2cc(O)c(O)c(O)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 7/20 0.51
▸ CA1 P00915 7/20 0.51
▸ CA2 P00918 7/20 0.51
▸ CA9 Q16790 7/20 0.51
▸ TDP1 Q9NUW8 1/20 0.48
▸ ITGB1 P05556 1/20 0.46
▸ ITGA4 P13612 1/20 0.46
▸ CSNK2A2 P19784 1/20 0.46
▸ CSNK2B P67870 1/20 0.46
▸ CSNK2A1 P68400 1/20 0.46
▸ CAMK2B Q13554 1/20 0.46
▸ KDM1A O60341 5/20 0.45
▸ PKM P14618 1/20 0.44
▸ SLC6A4 P31645 1/20 0.44
▸ FOLH1 Q04609 1/20 0.44
▸ F2 P00734 1/20 0.44
▸ PRSS1 P07477 1/20 0.44
▸ PRSS2 P07478 1/20 0.44
▸ PRSS3 P35030 1/20 0.44
▸ TPSAB1 Q15661 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20520171 0.88 PKM (0.49) CA12CA1CA2CA9TDP1
SCHEMBL18736330 0.83 CA12 (0.54) CA12CA1CA2CA9TDP1
SCHEMBL9412852 0.74 TDP1 (0.74) CA12CA1CA2CA9TDP1
SCHEMBL10000338 0.73 TDP1 (0.72) CA12CA1CA2CA9TDP1
SCHEMBL30821562 0.73 TDP1 (0.72) CA12CA1CA2CA9TDP1
SCHEMBL24420141 0.73 TDP1 (0.72) CA12CA1CA2CA9TDP1
SCHEMBL25014977 0.73 TDP1 (0.72) CA12CA1CA2CA9TDP1
SCHEMBL15895090 0.73 TDP1 (0.72) CA12CA1CA2CA9TDP1
SCHEMBL3256514 0.73 TDP1 (0.72) CA12CA1CA2CA9TDP1
SCHEMBL26598596 0.73 TDP1 (0.72) CA12CA1CA2CA9TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210369850-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF Centauri Therapeutics Limited (GB/GB) (GB) 2021-12-02 — — US disclosed
US-20210369850-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF Centauri Therapeutics Limited (GB/GB) (GB) 2021-12-02 — — US disclosed
US-10953100-B2 Compounds and therapeutic uses thereof CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) 2021-03-23 — — US disclosed
US-10953100-B2 Compounds and therapeutic uses thereof CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) 2021-03-23 — — US disclosed
US-20180280521-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) 2018-10-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210369850-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CD47, MYD88, NFATC1 CA12 2887/4885CA1 4372/4885CA2 4521/4885
US-10953100-B2 Compounds and therapeutic uses thereof CD47, MYD88, NFATC1 CA12 2887/4885CA1 4372/4885CA2 4521/4885
US-20180280521-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CD47, MYD88, NFATC1 CA12 2887/4885CA1 4372/4885CA2 4521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback